Clinical Trial Detail

NCT ID NCT03474497
Title Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of California, Davis
Indications

head and neck squamous cell carcinoma

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Therapies

Aldesleukin + Pembrolizumab + Radiotherapy

Age Groups: senior adult

No variant requirements are available.